Stay updated on Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.

Latest updates to the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedSignificant update: new operating-status notice and funding-related limitations are added, plus a version bump to v3.2.0; previous v3.1.0 deletion indicates a version upgrade.SummaryDifference4%

- Check30 days agoChange DetectedVersion metadata updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check45 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2, indicating a minor revision. The Back to Top element was removed; no other substantive content changes were detected.SummaryDifference0.2%

- Check52 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%

- Check59 days agoChange DetectedThe web page has been updated to include a new facility name and location, along with a list of publications related to gene therapy for neovascular age-related macular degeneration. The previous location details and some related topics have been removed.SummaryDifference6%

- Check74 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.